Regadenoson: A focused update

Journal of Nuclear Cardiology

Volumn 20, Issue 2, 2013, Pages 284-288

  Ghimire, Gopal ^a   Hage, Fadi G ^a,b   Heo, Jaekyeong ^a   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

adenosine; pharmacological stress testing; Regadenoson; SPECT

Indexed keywords

ADENOSINE; AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPYRIDAMOLE; REGADENOSON;

ABDOMINAL DISCOMFORT; AIRWAY RESISTANCE; ASTHMA; ATRIOVENTRICULAR BLOCK; BRONCHOSPASM; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIZZINESS; DRUG APPROVAL; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; EXERCISE; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; IMAGE QUALITY; LIVER DISEASE; MYOCARDIAL PERFUSION IMAGING; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THORAX PAIN;

CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; EXERCISE TEST; HUMANS; MYOCARDIAL PERFUSION IMAGING; PURINES; PYRAZOLES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS;

EID: 84879506978     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9661-3     Document Type: Review

References (24)

1. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trials. J Nucl Cardiol 2007;14:645-58.
2. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, on behalf of the ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. J Am Coll Cardiol Imaging 2008;1:307-16.
3. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
4. Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol 2012;19:126-41.
5. Iskandrian AE, Garcia EV, editors. Nuclear cardiac imaging: Principles and applications. 4th ed. Oxford: Oxford University Press; 2008.
6. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the advance MPI 2 trial. J Am Coll Cardiol Imaging 2009;2:959-68.
7. Sherwood M, Hage FG, Heo J, Shaw LJ, Cerqueira MD, Iskandrian AE. SPECT myocardial perfusion imaging as an endpoint. J Nucl Cardiol 2012;19:891-4.
8. Iskandrian AE, Garcia EV, Faber T, Mahmarian JJ. Automated assessment of serial SPECT myocardial perfusion images. J Nucl Cardiol 2009;16:6-9.
9. AlJaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010;105:133-5.
10. Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19:319-29.
11. AlJaroudi W, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol 2011;18:90-5.
12. Zoghbi GJ, Patel AD, Ershadi RE, Heo J, Bynon JS, Iskandrian AE. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol 2003;92:1066-71.
13. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo controlled trial. J Nucl Cardiol 2008;15:329-36.
14. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milken D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28.
15. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.
16. Thompson RC. Regadenoson stress in patients with asthma and COPD: A breath of fresh air. J Nucl Cardiol 2012;19:647-8.
17. Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milken D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective a (2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.
18. Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.
19. Partington S, Lanka V, Hainer J, Blankstein R, Skali H, Forman D, et al. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol 2012;19:970-8.
20. Thompson RC, Patil H, Thompson EC, Thomas GS, Al-Amoodi M, Kennedy KF, et al. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise. J Nucl Cardiol 2012. doi: 10.1007/s12350-012- 9660-4.
21. Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. J Am Coll Cardiol Imaging 2012;10:1014-21.
22. Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J 2011;162:356-62.
23. Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2011;18:1086-94.
24. Iqbal FM, AlJaroudi W, Sanam K, Mallela R, Heo J, Iskandrian AE, et al. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol 2012. doi: 10.1016/j.amjcard.2012.09.013.